+357 96 030922
info@marketpublishers.com

Global Biomanufacturing in Pharmaceutical Market Research Report 2026(Status and Outlook)

https://marketpublishers.com/r/GC58EE4D928CEN.html
Date: May 2026
Pages: 204
Price: US$ 3,200.00 (Single User License)
ID: GC58EE4D928CEN

Abstracts

In the pharmaceutical field, biomanufacturing refers to the use of living biological systems (such as mammalian, microbial, or plant cells) as "production factories" to transform complex biomolecules into drugs for the treatment or prevention of diseases through precisely controlled cultivation, fermentation, separation, and purification processes. This process differs from traditional chemical synthesis in that it emphasizes the correct folding, modification, and biological activity of macromolecules such as proteins and nucleic acids. It also requires strict adherence to regulatory standards such as cGMP to ensure product safety, efficacy, and batch consistency. Typical products include monoclonal antibodies, recombinant proteins, vaccines, and gene or cell therapy formulations, reflecting the shift in modern pharmaceutical manufacturing from chemical manufacturing to bio-driven innovation.The upstream biomanufacturing process in pharmaceuticals encompasses key supply chains such as equipment, reagents, and raw and excipient materials, forming the foundation of the entire industry chain. Equipment includes cell separation and elutriation machines, flow cytometers, cell culture incubators, biosafety cabinets, reactors (such as Wave, G-Rex, and CliniMACS Prodigy), nucleic acid synthesizers, HPLC separation systems, and fermenters. These equipment are widely used in the production of CAR-T, small nucleic acids, mRNA, monoclonal antibodies, and vaccines. Raw materials include DNA plasmids, enzymes, lipid nanoparticles, culture media, cell lines (such as CHO), cytokines, and chromatography media. The upstream industry landscape is still dominated by multinational giants such as GE Healthcare, Lonza, Miltenyi, Thermo Fisher, Cytiva, and Sartorius. Domestic companies such as LePure Biopharmaceuticals, Novozymes, GenScript, Nanovitamin Biotech, Lanxiao Technology, Dongfulong, and Chutian Technology are gradually replacing imports, particularly with breakthroughs in separation and purification media, as well as certain reagents and equipment. However, overall, gaps remain in high-end instruments and core consumables. Overall, the

+357 96 030922
info@marketpublishers.com

upstream industry demonstrates a pattern of "high technological barriers for multinational companies and rapid catching-up for local companies."The midstream sector primarily focuses on the R&D and production of biopharmaceuticals, including antibody drugs, CAR-T therapies, mRNA vaccines, small nucleic acid drugs, recombinant proteins, and blood products. This sector encompasses both large pharmaceutical companies and CDMO/CMO service providers. Globally, multinational pharmaceutical companies such as Roche, Pfizer, Novartis, Johnson & Johnson, and Bristol-Myers Squibb still dominate high-end innovation in the industry. In China, leading domestic companies such as WuXi AppTec, Corning Life Sciences, GenScript, Asymchem, Zhifei Biopharmaceuticals, Sinovac Biotech, and Kangtai Biologics are experiencing rapid growth, with some achieving international breakthroughs in vaccines, CDMOs, and antibody drugs. Geographically, North America and Europe are centers of innovation and R&D, while the Asia-Pacific region, particularly China, has gradually become a global hub for biomanufacturing production, creating a "European and American innovation, Asia-Pacific manufacturing" landscape. The midstream sector is currently transitioning towards digital factories, continuous flow production, and modularized capacity layouts, giving Chinese companies greater opportunities to directly adopt next-generation process standards when building new production capacity.The downstream biomanufacturing sector in the pharmaceutical industry primarily serves healthcare providers and patients. Typical users include large tertiary hospitals, specialized oncology centers, gene and cell therapy research institutions, and hematology hospitals, all of which are equipped to implement complex therapies such as CAR-T and gene therapy. For vaccines and conventional biopharmaceuticals, sales channels primarily rely on centralized government procurement, the medical insurance payment system, cold chain logistics, and commercial distribution. For example, domestic vaccines are distributed on a large scale through CDCs and vaccination sites, while blood products and monoclonal antibodies are distributed through hospital pharmacies, direct supply from pharmaceutical companies, and specialized distributors. With policy initiatives and evolving payment methods, volume-based procurement and medical insurance access have become key factors influencing the size of the downstream market. Furthermore, cold chain logistics (such as those provided by CIMC and Haier BioMedical) and third-party drug distribution (such as Jointown) play an indispensable role in ensuring transportation safety and efficiency. It can be said that the downstream sector is both the endpoint for biomanufacturing value realization and the core driver of market expansion and widespread adoption.The upstream process for antibody drugs centers on cell culture and purification processes. Their production relies on key raw materials such as high-quality cell culture media, enzyme tools, and CHO cell lines. Furthermore, pipettes, chromatography media, and disposable consumables are crucial for process stability. Regarding equipment, large-scale stirred tanks and

+357 96 030922
info@marketpublishers.com

airlift tanks are the mainstream culture methods, coupled with separation and purification systems to ensure antibody product quality. In terms of supply, international manufacturers such as Thermo Fisher Scientific, Roche, and Illumina maintain their dominant position, while domestic companies such as LePure Biopharmaceuticals, Novozymes, and GenScript are gradually achieving breakthroughs in culture media, cell lines, and some consumables, driving import substitution.The production process of recombinant protein drugs relies on genetically engineered vectors and host cell expression systems. The upstream process includes gene vector construction, cell culture, protein extraction, and chromatography purification. CHO cells remain the industry's mainstream host, and large-scale production is achieved through the integration of reactors, quality control instruments, and high-performance chromatography media. In the international market, giants such as Sartorius, Danaher (Cytiva), and GE Healthcare control high-end equipment and purification processes, while Chinese companies such as OptoMed, Sino Biological, and Labtech are gradually becoming competitive in some equipment and reagents. Overall, this sector demonstrates continued reliance on multinational companies, while domestic companies are rapidly catching up through technological accumulation.The upstream process of blood products relies on the collection, separation, and purification of healthy human plasma, making apheresis centers the only legal source of raw materials. In terms of technology, traditional low-temperature ethanol separation processes are still widely used, but they lack purity and efficiency. Therefore, column chromatography and ultrafiltration technologies are gradually being introduced to improve protein yield and product safety. Upstream equipment includes plasma separation equipment, chromatography systems, and filtration consumables, with key suppliers primarily concentrated in the European and American markets. While domestic companies such as Hualan Biotechnology, Tiantan Biotechnology, and Shanghai RAAS have advantages in plasma collection and certain process technologies, they still rely on imports for high-end chromatography media and equipment.The upstream component of vaccines is relatively complex, encompassing a variety of raw materials such as culture media, antibiotics, enzyme tools, liposomes, drug delivery vehicles, reagents, and packaging materials. At the equipment level, fermenters, reactors, separation and purification systems, and quality control instruments are essential core components. The global market is dominated by multinational giants such as Thermo Fisher Scientific, Danaher, and Sartorius, whose products are highly competitive in terms of quality and GMP standards. Chinese companies such as LePure Biotechnology, Novozymes, Dongfulong, Chutian Technology, and Jiankai Technology have gradually established scale in culture media, certain equipment, and purification consumables, demonstrating strong industrial responsiveness, particularly within the COVID-19 vaccine supply chain. The upstream process of CAR-T cell therapy relies on high-end

+357 96 030922
info@marketpublishers.com

equipment and key reagents. The production process relies on equipment such as flow cytometers, blood cell separation and elutriation machines, cell culture incubators, and biosafety cabinets. It also requires consumables such as magnetic bead enrichment columns, electroporators, and T-flasks, culture bags, and Wave reactors. Cytokines and transfection reagents are key ingredients for ensuring cell viability and the success rate of gene delivery. Currently, international companies such as GE Healthcare, Miltenyi, Lonza, and Thermo Fisher Scientific hold a commanding position in this field. While domestic companies offer some competitiveness in consumables pricing, their overall quality lags behind international standards, leading local R&D companies to rely more heavily on imported products.The upstream process of small nucleic acid drugs primarily focuses on synthesis and purification. Core equipment includes solid-phase nucleic acid synthesizers and reversed-phase HPLC separation systems, combined with high-purity nucleotide monomers and reagents to complete the synthesis process. The international market is dominated by companies such as Cytiva (a Danaher subsidiary) and Thermo Fisher Scientific, which have established technological barriers to GMP-grade equipment and key consumables. In China, Nanotech, Lanxiao Technology, and Boglon are gradually replacing domestically produced materials in separation and purification fillers, driving down production costs. However, they still rely on imports for industrial synthesis equipment. As the industry scales up, breakthroughs in the domestic supply chain are seen as key to reducing costs and improving domestic controllability.In recent years, the pharmaceutical industry's R&D focus has shifted from solely focusing on the discovery and optimization of small molecule drugs. Driven by biomanufacturing, the product portfolio has evolved into a multimodal, biology-centric landscape. While traditional proteins and monoclonal antibodies remain the bulk of the market, manufacturing processes are constantly being optimized to improve yield and quality consistency. Meanwhile, emerging therapeutic modalities such as cell and gene therapies, mRNA, nucleic acid therapies, and gene editing-related products are placing new demands on biomanufacturing. Upstream cell line development, expression system optimization, vector production, sterile and pyrogen-free downstream purification, and process stability for both in vitro and in vivo delivery systems have all become key R&D priorities. Consequently, the boundaries between R&D and manufacturing are becoming increasingly blurred: early-stage molecular design must consider manufacturability for scalable production, while process development, in turn, influences clinical dosing regimens and development cadence. With the maturity of AI/data-driven design, synthetic biology, and high-throughput screening technologies, the path from early target identification to producible biologics has been significantly shortened. This, in turn, requires manufacturing teams to engage earlier in early drug development to ensure that candidate molecules do not encounter unresolvable process bottlenecks when entering mid- to late-stage large-scale production. As a result, R&D trends are

+357 96 030922
info@marketpublishers.com

showing a significant shift from single-molecule innovation to molecule-process co-design. This trend will continue to intensify, driving companies to adjust their R&D organizational structures and investment allocations to balance scientific innovation with production feasibility.The technological evolution of biomanufacturing is undergoing a transition from traditional batch processes to continuous production and intelligent manufacturing. Continuous bioreactors, real-time release testing (RTRT), online process analytical technology (PAT), and closed-loop automation systems can significantly improve unit capacity utilization, shorten release times, and reduce human errors, while also enabling rapid scale-up and flexible capacity adjustments. Digitalization (including production-level data platforms, AI-driven process optimization, and predictive maintenance) enables faster development of relationships between process parameters and quality attributes, accelerating improvements in batch yields. Regarding platformization, product lines such as monoclonal antibodies (mAbs) and viral vectors are increasingly adopting standardized platform processes: reusable expression systems, universal downstream purification columns, and modular facilities (such as mobile or "factory-as-a-module") to reduce the cost and time required to introduce new products. Green manufacturing and low-carbon processes are also gradually being incorporated into the technology pipeline, such as reducing solvent use and improving resource recycling. Overall, these technologies are characterized by high automation, strong data reliance, and platform-based reuse. This places higher demands on companies' R&D organizations, technical reserves, and capital investment, while also providing companies with advanced processes with a lasting competitive advantage.The biomanufacturing sector is characterized by significant scale and technology concentration. Global large pharmaceutical companies and leading CDMOs/CMOs dominate high-end production capacity and complex process capabilities. At the same time, a large number of specialized small and medium-sized enterprises, contract research and production organizations, and technical service providers have emerged in the market, forming a complex network of collaborations. Large innovative pharmaceutical companies, driven by flexibility and cost considerations, are increasingly outsourcing some manufacturing to third-party CDMOs with scale and regulatory compliance, allowing them to focus their resources on core R&D and commercialization. In turn, CDMOs are rapidly increasing their bargaining power within the supply chain by investing in serialization, expanding sterile biologics production capacity, and acquiring key process patents through mergers and acquisitions. Furthermore, cross-border collaborations, licensing, co-development, and joint ventures are becoming common strategies for rapidly entering new markets or securing regional regulatory compliance pathways. It's worth noting that collaboration doesn't necessarily mean weakening competition: Building on platformization and standardization, companies are creating competitive barriers through differentiated

+357 96 030922
info@marketpublishers.com

services, patent portfolios, quality systems, and delivery capabilities. In short, the industry's key characteristics include a strong platform effect, a refined division of labor, and regularized collaboration. Within this ecosystem, there's both concentrated competition among large-scale companies and the rapid growth of small and medium-sized players relying on specialized capabilities.

The global Biomanufacturing in Pharmaceutical market size was estimated at USD 518560.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 9.40% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Biomanufacturing in Pharmaceutical market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Biomanufacturing in Pharmaceutical market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Biomanufacturing in Pharmaceutical market.

Global Biomanufacturing in Pharmaceutical Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-

+357 96 030922
info@marketpublishers.com

user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

Roche

Merck

Novo Nordisk

Sanofi

Johnson & Johnson

AbbVie

Amgen

AstraZeneca

Takeda Pharmaceuticals

Bristol-Myers Squib

Pfizer

Eli Lilly

Novartis

GSK

+357 96 030922
info@marketpublishers.com

CSL Limited

Regeneron Pharmaceuticals

Gilford

Biogen

GileadSciences

Moderna

Sarepta Therapeutics, Inc.

Changchun High-Tech Industry

Sino Biopharmaceutical Limited

Sobi

3SBio Inc.

Beijing Tiantan Biological

Innovent Biologics

Qilu Pharmaceutical

Boehringer Ingelheim

BeiGene

Market Segmentation (by Type)

Antibody Drugs

Recombinant Protein Drugs

+357 96 030922
info@marketpublishers.com

Blood Products

Vaccine Preparations

CAR-T Drugs

Small Nucleic Acid Drugs

Others

Market Segmentation (by Application)

Oncology

Infectious Diseases

Immune and Inflammatory Diseases

Endocrine and Metabolic Diseases

Neurological Diseases

Hematologic Diseases

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

+357 96 030922
info@marketpublishers.com

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Biomanufacturing in Pharmaceutical Market

Overview of the regional outlook of the Biomanufacturing in Pharmaceutical Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Biomanufacturing in Pharmaceutical Market and its likely evolution in the short to mid-

+357 96 030922
info@marketpublishers.com

term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Biomanufacturing in Pharmaceutical, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

+357 96 030922
info@marketpublishers.com

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

+357 96 030922
info@marketpublishers.com

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

+357 96 030922
info@marketpublishers.com

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Biomanufacturing in Pharmaceutical
1.2 Key Market Segments
  1.2.1 Biomanufacturing in Pharmaceutical Segment by Type
  1.2.2 Biomanufacturing in Pharmaceutical Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 BIOMANUFACTURING IN PHARMACEUTICAL MARKET OVERVIEW

2.1 Global Market Overview
  2.1.1 Global Biomanufacturing in Pharmaceutical Market Size (M USD) Estimates and Forecasts (2020-2035)
  2.1.2 Global Biomanufacturing in Pharmaceutical Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 BIOMANUFACTURING IN PHARMACEUTICAL MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant
3.2 Global Biomanufacturing in Pharmaceutical Product Life Cycle
3.3 Global Biomanufacturing in Pharmaceutical Sales by Manufacturers (2020-2025)
3.4 Global Biomanufacturing in Pharmaceutical Revenue Market Share by Manufacturers (2020-2025)
3.5 Biomanufacturing in Pharmaceutical Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Biomanufacturing in Pharmaceutical Average Price by Manufacturers (2020-2025)
3.7 Manufacturers' Manufacturing Sites, Areas Served, and Product Types
3.8 Biomanufacturing in Pharmaceutical Market Competitive Situation and Trends

+357 96 030922
info@marketpublishers.com

3.8.1 Biomanufacturing in Pharmaceutical Market Concentration Rate
3.8.2 Global 5 and 10 Largest Biomanufacturing in Pharmaceutical Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion

4 BIOMANUFACTURING IN PHARMACEUTICAL INDUSTRY CHAIN ANALYSIS

4.1 Biomanufacturing in Pharmaceutical Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF BIOMANUFACTURING IN PHARMACEUTICAL MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Biomanufacturing in Pharmaceutical Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy – April 2025
5.6.3 Global Trade Frictions and Their Impacts to Biomanufacturing in Pharmaceutical Market
5.7 ESG Ratings of Leading Companies

6 BIOMANUFACTURING IN PHARMACEUTICAL MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

+357 96 030922
info@marketpublishers.com

6.2 Global Biomanufacturing in Pharmaceutical Sales Market Share by Type (2020-2025)
6.3 Global Biomanufacturing in Pharmaceutical Market Size by Type (2020-2025)
6.4 Global Biomanufacturing in Pharmaceutical Price by Type (2020-2025)

7 BIOMANUFACTURING IN PHARMACEUTICAL MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Biomanufacturing in Pharmaceutical Market Sales by Application (2020-2025)
7.3 Global Biomanufacturing in Pharmaceutical Market Size (M USD) by Application (2020-2025)
7.4 Global Biomanufacturing in Pharmaceutical Sales Growth Rate by Application (2020-2025)

8 BIOMANUFACTURING IN PHARMACEUTICAL MARKET SALES BY REGION

8.1 Global Biomanufacturing in Pharmaceutical Sales by Region
  8.1.1 Global Biomanufacturing in Pharmaceutical Sales by Region
  8.1.2 Global Biomanufacturing in Pharmaceutical Sales Market Share by Region
8.2 Global Biomanufacturing in Pharmaceutical Market Size by Region
  8.2.1 Global Biomanufacturing in Pharmaceutical Market Size by Region
  8.2.2 Global Biomanufacturing in Pharmaceutical Market Size by Region
8.3 North America
  8.3.1 North America Biomanufacturing in Pharmaceutical Sales by Country
  8.3.2 North America Biomanufacturing in Pharmaceutical Market Size by Country
  8.3.3 U.S. Market Overview
  8.3.4 Canada Market Overview
  8.3.5 Mexico Market Overview
8.4 Europe
  8.4.1 Europe Biomanufacturing in Pharmaceutical Sales by Country
  8.4.2 Europe Biomanufacturing in Pharmaceutical Market Size by Country
  8.4.3 Germany Market Overview
  8.4.4 France Market Overview
  8.4.5 U.K. Market Overview
  8.4.6 Italy Market Overview
  8.4.7 Spain Market Overview
8.5 Asia Pacific

+357 96 030922
info@marketpublishers.com

8.5.1 Asia Pacific Biomanufacturing in Pharmaceutical Sales by Region
8.5.2 Asia Pacific Biomanufacturing in Pharmaceutical Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Biomanufacturing in Pharmaceutical Sales by Country
8.6.2 South America Biomanufacturing in Pharmaceutical Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Biomanufacturing in Pharmaceutical Sales by Region
8.7.2 Middle East and Africa Biomanufacturing in Pharmaceutical Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview

9 BIOMANUFACTURING IN PHARMACEUTICAL MARKET PRODUCTION BY REGION

9.1 Global Production of Biomanufacturing in Pharmaceutical by Region(2020-2025)
9.2 Global Biomanufacturing in Pharmaceutical Revenue Market Share by Region (2020-2025)
9.3 Global Biomanufacturing in Pharmaceutical Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Biomanufacturing in Pharmaceutical Production
9.4.1 North America Biomanufacturing in Pharmaceutical Production Growth Rate (2020-2025)
9.4.2 North America Biomanufacturing in Pharmaceutical Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Biomanufacturing in Pharmaceutical Production
9.5.1 Europe Biomanufacturing in Pharmaceutical Production Growth Rate (2020-2025)

+357 96 030922
info@marketpublishers.com

9.5.2 Europe Biomanufacturing in Pharmaceutical Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Biomanufacturing in Pharmaceutical Production (2020-2025)
9.6.1 Japan Biomanufacturing in Pharmaceutical Production Growth Rate (2020-2025)
9.6.2 Japan Biomanufacturing in Pharmaceutical Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Biomanufacturing in Pharmaceutical Production (2020-2025)
9.7.1 China Biomanufacturing in Pharmaceutical Production Growth Rate (2020-2025)
9.7.2 China Biomanufacturing in Pharmaceutical Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Roche
10.1.1 Roche Basic Information
10.1.2 Roche Biomanufacturing in Pharmaceutical Product Overview
10.1.3 Roche Biomanufacturing in Pharmaceutical Product Market Performance
10.1.4 Roche Business Overview
10.1.5 Roche SWOT Analysis
10.1.6 Roche Recent Developments
10.2 Merck
10.2.1 Merck Basic Information
10.2.2 Merck Biomanufacturing in Pharmaceutical Product Overview
10.2.3 Merck Biomanufacturing in Pharmaceutical Product Market Performance
10.2.4 Merck Business Overview
10.2.5 Merck SWOT Analysis
10.2.6 Merck Recent Developments
10.3 Novo Nordisk
10.3.1 Novo Nordisk Basic Information
10.3.2 Novo Nordisk Biomanufacturing in Pharmaceutical Product Overview
10.3.3 Novo Nordisk Biomanufacturing in Pharmaceutical Product Market Performance
10.3.4 Novo Nordisk Business Overview
10.3.5 Novo Nordisk SWOT Analysis
10.3.6 Novo Nordisk Recent Developments
10.4 Sanofi
10.4.1 Sanofi Basic Information
10.4.2 Sanofi Biomanufacturing in Pharmaceutical Product Overview
10.4.3 Sanofi Biomanufacturing in Pharmaceutical Product Market Performance
10.4.4 Sanofi Business Overview

+357 96 030922
info@marketpublishers.com

10.4.5 Sanofi Recent Developments
10.5 Johnson and Johnson
10.5.1 Johnson and Johnson Basic Information
10.5.2 Johnson and Johnson Biomanufacturing in Pharmaceutical Product Overview
10.5.3 Johnson and Johnson Biomanufacturing in Pharmaceutical Product Market Performance
10.5.4 Johnson and Johnson Business Overview
10.5.5 Johnson and Johnson Recent Developments
10.6 AbbVie
10.6.1 AbbVie Basic Information
10.6.2 AbbVie Biomanufacturing in Pharmaceutical Product Overview
10.6.3 AbbVie Biomanufacturing in Pharmaceutical Product Market Performance
10.6.4 AbbVie Business Overview
10.6.5 AbbVie Recent Developments
10.7 Amgen
10.7.1 Amgen Basic Information
10.7.2 Amgen Biomanufacturing in Pharmaceutical Product Overview
10.7.3 Amgen Biomanufacturing in Pharmaceutical Product Market Performance
10.7.4 Amgen Business Overview
10.7.5 Amgen Recent Developments
10.8 AstraZeneca
10.8.1 AstraZeneca Basic Information
10.8.2 AstraZeneca Biomanufacturing in Pharmaceutical Product Overview
10.8.3 AstraZeneca Biomanufacturing in Pharmaceutical Product Market Performance
10.8.4 AstraZeneca Business Overview
10.8.5 AstraZeneca Recent Developments
10.9 Takeda Pharmaceuticals
10.9.1 Takeda Pharmaceuticals Basic Information
10.9.2 Takeda Pharmaceuticals Biomanufacturing in Pharmaceutical Product Overview
10.9.3 Takeda Pharmaceuticals Biomanufacturing in Pharmaceutical Product Market Performance
10.9.4 Takeda Pharmaceuticals Business Overview
10.9.5 Takeda Pharmaceuticals Recent Developments
10.10 Bristol-Myers Squib
10.10.1 Bristol-Myers Squib Basic Information
10.10.2 Bristol-Myers Squib Biomanufacturing in Pharmaceutical Product Overview
10.10.3 Bristol-Myers Squib Biomanufacturing in Pharmaceutical Product Market Performance

+357 96 030922
info@marketpublishers.com

10.10.4 Bristol-Myers Squib Business Overview
10.10.5 Bristol-Myers Squib Recent Developments
10.11 Pfizer
10.11.1 Pfizer Basic Information
10.11.2 Pfizer Biomanufacturing in Pharmaceutical Product Overview
10.11.3 Pfizer Biomanufacturing in Pharmaceutical Product Market Performance
10.11.4 Pfizer Business Overview
10.11.5 Pfizer Recent Developments
10.12 Eli Lilly
10.12.1 Eli Lilly Basic Information
10.12.2 Eli Lilly Biomanufacturing in Pharmaceutical Product Overview
10.12.3 Eli Lilly Biomanufacturing in Pharmaceutical Product Market Performance
10.12.4 Eli Lilly Business Overview
10.12.5 Eli Lilly Recent Developments
10.13 Novartis
10.13.1 Novartis Basic Information
10.13.2 Novartis Biomanufacturing in Pharmaceutical Product Overview
10.13.3 Novartis Biomanufacturing in Pharmaceutical Product Market Performance
10.13.4 Novartis Business Overview
10.13.5 Novartis Recent Developments
10.14 GSK
10.14.1 GSK Basic Information
10.14.2 GSK Biomanufacturing in Pharmaceutical Product Overview
10.14.3 GSK Biomanufacturing in Pharmaceutical Product Market Performance
10.14.4 GSK Business Overview
10.14.5 GSK Recent Developments
10.15 CSL Limited
10.15.1 CSL Limited Basic Information
10.15.2 CSL Limited Biomanufacturing in Pharmaceutical Product Overview
10.15.3 CSL Limited Biomanufacturing in Pharmaceutical Product Market Performance
10.15.4 CSL Limited Business Overview
10.15.5 CSL Limited Recent Developments
10.16 Regeneron Pharmaceuticals
10.16.1 Regeneron Pharmaceuticals Basic Information
10.16.2 Regeneron Pharmaceuticals Biomanufacturing in Pharmaceutical Product Overview
10.16.3 Regeneron Pharmaceuticals Biomanufacturing in Pharmaceutical Product Market Performance
10.16.4 Regeneron Pharmaceuticals Business Overview

+357 96 030922
info@marketpublishers.com

10.16.5 Regeneron Pharmaceuticals Recent Developments
10.17 Gilford
10.17.1 Gilford Basic Information
10.17.2 Gilford Biomanufacturing in Pharmaceutical Product Overview
10.17.3 Gilford Biomanufacturing in Pharmaceutical Product Market Performance
10.17.4 Gilford Business Overview
10.17.5 Gilford Recent Developments
10.18 Biogen
10.18.1 Biogen Basic Information
10.18.2 Biogen Biomanufacturing in Pharmaceutical Product Overview
10.18.3 Biogen Biomanufacturing in Pharmaceutical Product Market Performance
10.18.4 Biogen Business Overview
10.18.5 Biogen Recent Developments
10.19 GileadSciences
10.19.1 GileadSciences Basic Information
10.19.2 GileadSciences Biomanufacturing in Pharmaceutical Product Overview
10.19.3 GileadSciences Biomanufacturing in Pharmaceutical Product Market Performance
10.19.4 GileadSciences Business Overview
10.19.5 GileadSciences Recent Developments
10.20 Moderna
10.20.1 Moderna Basic Information
10.20.2 Moderna Biomanufacturing in Pharmaceutical Product Overview
10.20.3 Moderna Biomanufacturing in Pharmaceutical Product Market Performance
10.20.4 Moderna Business Overview
10.20.5 Moderna Recent Developments
10.21 Sarepta Therapeutics, Inc.
10.21.1 Sarepta Therapeutics, Inc. Basic Information
10.21.2 Sarepta Therapeutics, Inc. Biomanufacturing in Pharmaceutical Product Overview
10.21.3 Sarepta Therapeutics, Inc. Biomanufacturing in Pharmaceutical Product Market Performance
10.21.4 Sarepta Therapeutics, Inc. Business Overview
10.21.5 Sarepta Therapeutics, Inc. Recent Developments
10.22 Changchun High-Tech Industry
10.22.1 Changchun High-Tech Industry Basic Information
10.22.2 Changchun High-Tech Industry Biomanufacturing in Pharmaceutical Product Overview
10.22.3 Changchun High-Tech Industry Biomanufacturing in Pharmaceutical Product

+357 96 030922
info@marketpublishers.com

Market Performance
10.22.4 Changchun High-Tech Industry Business Overview
10.22.5 Changchun High-Tech Industry Recent Developments
10.23 Sino Biopharmaceutical Limited
10.23.1 Sino Biopharmaceutical Limited Basic Information
10.23.2 Sino Biopharmaceutical Limited Biomanufacturing in Pharmaceutical Product Overview
10.23.3 Sino Biopharmaceutical Limited Biomanufacturing in Pharmaceutical Product Market Performance
10.23.4 Sino Biopharmaceutical Limited Business Overview
10.23.5 Sino Biopharmaceutical Limited Recent Developments
10.24 Sobi
10.24.1 Sobi Basic Information
10.24.2 Sobi Biomanufacturing in Pharmaceutical Product Overview
10.24.3 Sobi Biomanufacturing in Pharmaceutical Product Market Performance
10.24.4 Sobi Business Overview
10.24.5 Sobi Recent Developments
10.25 3SBio Inc.
10.25.1 3SBio Inc. Basic Information
10.25.2 3SBio Inc. Biomanufacturing in Pharmaceutical Product Overview
10.25.3 3SBio Inc. Biomanufacturing in Pharmaceutical Product Market Performance
10.25.4 3SBio Inc. Business Overview
10.25.5 3SBio Inc. Recent Developments
10.26 Beijing Tiantan Biological
10.26.1 Beijing Tiantan Biological Basic Information
10.26.2 Beijing Tiantan Biological Biomanufacturing in Pharmaceutical Product Overview
10.26.3 Beijing Tiantan Biological Biomanufacturing in Pharmaceutical Product Market Performance
10.26.4 Beijing Tiantan Biological Business Overview
10.26.5 Beijing Tiantan Biological Recent Developments
10.27 Innovent Biologics
10.27.1 Innovent Biologics Basic Information
10.27.2 Innovent Biologics Biomanufacturing in Pharmaceutical Product Overview
10.27.3 Innovent Biologics Biomanufacturing in Pharmaceutical Product Market Performance
10.27.4 Innovent Biologics Business Overview
10.27.5 Innovent Biologics Recent Developments
10.28 Qilu Pharmaceutical

+357 96 030922
info@marketpublishers.com

10.28.1 Qilu Pharmaceutical Basic Information
10.28.2 Qilu Pharmaceutical Biomanufacturing in Pharmaceutical Product Overview
10.28.3 Qilu Pharmaceutical Biomanufacturing in Pharmaceutical Product Market Performance
10.28.4 Qilu Pharmaceutical Business Overview
10.28.5 Qilu Pharmaceutical Recent Developments
10.29 Boehringer Ingelheim
10.29.1 Boehringer Ingelheim Basic Information
10.29.2 Boehringer Ingelheim Biomanufacturing in Pharmaceutical Product Overview
10.29.3 Boehringer Ingelheim Biomanufacturing in Pharmaceutical Product Market Performance
10.29.4 Boehringer Ingelheim Business Overview
10.29.5 Boehringer Ingelheim Recent Developments
10.30 BeiGene
10.30.1 BeiGene Basic Information
10.30.2 BeiGene Biomanufacturing in Pharmaceutical Product Overview
10.30.3 BeiGene Biomanufacturing in Pharmaceutical Product Market Performance
10.30.4 BeiGene Business Overview
10.30.5 BeiGene Recent Developments

11 BIOMANUFACTURING IN PHARMACEUTICAL MARKET FORECAST BY REGION

11.1 Global Biomanufacturing in Pharmaceutical Market Size Forecast
11.2 Global Biomanufacturing in Pharmaceutical Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Biomanufacturing in Pharmaceutical Market Size Forecast by Country
11.2.3 Asia Pacific Biomanufacturing in Pharmaceutical Market Size Forecast by Region
11.2.4 South America Biomanufacturing in Pharmaceutical Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Biomanufacturing in Pharmaceutical by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)

12.1 Global Biomanufacturing in Pharmaceutical Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Biomanufacturing in Pharmaceutical by Type (2026-2035)

+357 96 030922
info@marketpublishers.com

12.1.2 Global Biomanufacturing in Pharmaceutical Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Biomanufacturing in Pharmaceutical by Type (2026-2035)
12.2 Global Biomanufacturing in Pharmaceutical Market Forecast by Application (2026-2035)
12.2.1 Global Biomanufacturing in Pharmaceutical Sales (K Units) Forecast by Application
12.2.2 Global Biomanufacturing in Pharmaceutical Market Size (M USD) Forecast by Application (2026-2035)

13 CONCLUSION AND KEY FINDINGS

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Biomanufacturing in Pharmaceutical Market Size by Type (M USD)
Table 4. Global Biomanufacturing in Pharmaceutical Market Size by Application
Table 5. Biomanufacturing in Pharmaceutical Market Size Comparison by Region (M USD)
Table 6. Global Biomanufacturing in Pharmaceutical Sales (K Units) by Manufacturers (2020-2025)
Table 7. Global Biomanufacturing in Pharmaceutical Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Biomanufacturing in Pharmaceutical Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Biomanufacturing in Pharmaceutical Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biomanufacturing in Pharmaceutical as of 2025)
Table 11. Global Market Biomanufacturing in Pharmaceutical Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 12. Manufacturers’ Manufacturing Sites, Areas Served
Table 13. Manufacturers’ Product Type
Table 14. Global Biomanufacturing in Pharmaceutical Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Biomanufacturing in Pharmaceutical Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Biomanufacturing in Pharmaceutical Sales by Type (K Units)

+357 96 030922
info@marketpublishers.com

Table 27. Global Biomanufacturing in Pharmaceutical Market Size by Type (M USD)
Table 28. Global Biomanufacturing in Pharmaceutical Sales (K Units) by Type (2020-2025)
Table 29. Global Biomanufacturing in Pharmaceutical Sales Market Share by Type (2020-2025)
Table 30. Global Biomanufacturing in Pharmaceutical Market Size (M USD) by Type (2020-2025)
Table 31. Global Biomanufacturing in Pharmaceutical Market Share by Type (2020-2025)
Table 32. Global Biomanufacturing in Pharmaceutical Price (USD/Unit) by Type (2020-2025)
Table 33. Global Biomanufacturing in Pharmaceutical Sales (K Units) by Application
Table 34. Global Biomanufacturing in Pharmaceutical Market Size by Application
Table 35. Global Biomanufacturing in Pharmaceutical Sales by Application (2020-2025) & (K Units)
Table 36. Global Biomanufacturing in Pharmaceutical Sales Market Share by Application (2020-2025)
Table 37. Global Biomanufacturing in Pharmaceutical Market Size by Application (2020-2025) & (M USD)
Table 38. Global Biomanufacturing in Pharmaceutical Market Share by Application (2020-2025)
Table 39. Global Biomanufacturing in Pharmaceutical Sales Growth Rate by Application (2020-2025)
Table 40. Global Biomanufacturing in Pharmaceutical Sales by Region (2020-2025) & (K Units)
Table 41. Global Biomanufacturing in Pharmaceutical Sales Market Share by Region (2020-2025)
Table 42. Global Biomanufacturing in Pharmaceutical Market Size by Region (2020-2025) & (M USD)
Table 43. Global Biomanufacturing in Pharmaceutical Market Size by Region (2020-2025)
Table 44. North America Biomanufacturing in Pharmaceutical Sales by Country (2020-2025) & (K Units)
Table 45. North America Biomanufacturing in Pharmaceutical Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Biomanufacturing in Pharmaceutical Sales by Country (2020-2025) & (K Units)
Table 47. Europe Biomanufacturing in Pharmaceutical Market Size by Country (2020-2025) & (M USD)

+357 96 030922
info@marketpublishers.com

Table 48. Asia Pacific Biomanufacturing in Pharmaceutical Sales by Region (2020-2025) & (K Units)
Table 49. Asia Pacific Biomanufacturing in Pharmaceutical Market Size by Region (2020-2025) & (M USD)
Table 50. South America Biomanufacturing in Pharmaceutical Sales by Country (2020-2025) & (K Units)
Table 51. South America Biomanufacturing in Pharmaceutical Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Biomanufacturing in Pharmaceutical Sales by Region (2020-2025) & (K Units)
Table 53. Middle East and Africa Biomanufacturing in Pharmaceutical Market Size by Region (2020-2025) & (M USD)
Table 54. Global Biomanufacturing in Pharmaceutical Production (K Units) by Region(2020-2025)
Table 55. Global Biomanufacturing in Pharmaceutical Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Biomanufacturing in Pharmaceutical Revenue Market Share by Region (2020-2025)
Table 57. Global Biomanufacturing in Pharmaceutical Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. North America Biomanufacturing in Pharmaceutical Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. Europe Biomanufacturing in Pharmaceutical Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Japan Biomanufacturing in Pharmaceutical Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 61. China Biomanufacturing in Pharmaceutical Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 62. Roche Basic Information
Table 63. Roche Biomanufacturing in Pharmaceutical Product Overview
Table 64. Roche Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. Roche Business Overview
Table 66. Roche SWOT Analysis
Table 67. Roche Recent Developments
Table 68. Merck Basic Information
Table 69. Merck Biomanufacturing in Pharmaceutical Product Overview
Table 70. Merck Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)

+357 96 030922
info@marketpublishers.com

Table 71. Merck Business Overview
Table 72. Merck SWOT Analysis
Table 73. Merck Recent Developments
Table 74. Novo Nordisk Basic Information
Table 75. Novo Nordisk Biomanufacturing in Pharmaceutical Product Overview
Table 76. Novo Nordisk Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. Novo Nordisk Business Overview
Table 78. Novo Nordisk SWOT Analysis
Table 79. Novo Nordisk Recent Developments
Table 80. Sanofi Basic Information
Table 81. Sanofi Biomanufacturing in Pharmaceutical Product Overview
Table 82. Sanofi Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Sanofi Business Overview
Table 84. Sanofi Recent Developments
Table 85. Johnson and Johnson Basic Information
Table 86. Johnson and Johnson Biomanufacturing in Pharmaceutical Product Overview
Table 87. Johnson and Johnson Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Johnson and Johnson Business Overview
Table 89. Johnson and Johnson Recent Developments
Table 90. AbbVie Basic Information
Table 91. AbbVie Biomanufacturing in Pharmaceutical Product Overview
Table 92. AbbVie Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. AbbVie Business Overview
Table 94. AbbVie Recent Developments
Table 95. Amgen Basic Information
Table 96. Amgen Biomanufacturing in Pharmaceutical Product Overview
Table 97. Amgen Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Amgen Business Overview
Table 99. Amgen Recent Developments
Table 100. AstraZeneca Basic Information
Table 101. AstraZeneca Biomanufacturing in Pharmaceutical Product Overview
Table 102. AstraZeneca Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. AstraZeneca Business Overview

+357 96 030922
info@marketpublishers.com

Table 104. AstraZeneca Recent Developments
Table 105. Takeda Pharmaceuticals Basic Information
Table 106. Takeda Pharmaceuticals Biomanufacturing in Pharmaceutical Product Overview
Table 107. Takeda Pharmaceuticals Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Takeda Pharmaceuticals Business Overview
Table 109. Takeda Pharmaceuticals Recent Developments
Table 110. Bristol-Myers Squib Basic Information
Table 111. Bristol-Myers Squib Biomanufacturing in Pharmaceutical Product Overview
Table 112. Bristol-Myers Squib Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Bristol-Myers Squib Business Overview
Table 114. Bristol-Myers Squib Recent Developments
Table 115. Pfizer Basic Information
Table 116. Pfizer Biomanufacturing in Pharmaceutical Product Overview
Table 117. Pfizer Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Pfizer Business Overview
Table 119. Pfizer Recent Developments
Table 120. Eli Lilly Basic Information
Table 121. Eli Lilly Biomanufacturing in Pharmaceutical Product Overview
Table 122. Eli Lilly Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Eli Lilly Business Overview
Table 124. Eli Lilly Recent Developments
Table 125. Novartis Basic Information
Table 126. Novartis Biomanufacturing in Pharmaceutical Product Overview
Table 127. Novartis Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. Novartis Business Overview
Table 129. Novartis Recent Developments
Table 130. GSK Basic Information
Table 131. GSK Biomanufacturing in Pharmaceutical Product Overview
Table 132. GSK Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. GSK Business Overview
Table 134. GSK Recent Developments
Table 135. CSL Limited Basic Information

+357 96 030922
info@marketpublishers.com

Table 136. CSL Limited Biomanufacturing in Pharmaceutical Product Overview
Table 137. CSL Limited Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 138. CSL Limited Business Overview
Table 139. CSL Limited Recent Developments
Table 140. Regeneron Pharmaceuticals Basic Information
Table 141. Regeneron Pharmaceuticals Biomanufacturing in Pharmaceutical Product Overview
Table 142. Regeneron Pharmaceuticals Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 143. Regeneron Pharmaceuticals Business Overview
Table 144. Regeneron Pharmaceuticals Recent Developments
Table 145. Gilford Basic Information
Table 146. Gilford Biomanufacturing in Pharmaceutical Product Overview
Table 147. Gilford Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 148. Gilford Business Overview
Table 149. Gilford Recent Developments
Table 150. Biogen Basic Information
Table 151. Biogen Biomanufacturing in Pharmaceutical Product Overview
Table 152. Biogen Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 153. Biogen Business Overview
Table 154. Biogen Recent Developments
Table 155. GileadSciences Basic Information
Table 156. GileadSciences Biomanufacturing in Pharmaceutical Product Overview
Table 157. GileadSciences Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 158. GileadSciences Business Overview
Table 159. GileadSciences Recent Developments
Table 160. Moderna Basic Information
Table 161. Moderna Biomanufacturing in Pharmaceutical Product Overview
Table 162. Moderna Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 163. Moderna Business Overview
Table 164. Moderna Recent Developments
Table 165. Sarepta Therapeutics, Inc. Basic Information
Table 166. Sarepta Therapeutics, Inc. Biomanufacturing in Pharmaceutical Product Overview

+357 96 030922
info@marketpublishers.com

Table 167. Sarepta Therapeutics, Inc. Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 168. Sarepta Therapeutics, Inc. Business Overview
Table 169. Sarepta Therapeutics, Inc. Recent Developments
Table 170. Changchun High-Tech Industry Basic Information
Table 171. Changchun High-Tech Industry Biomanufacturing in Pharmaceutical Product Overview
Table 172. Changchun High-Tech Industry Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 173. Changchun High-Tech Industry Business Overview
Table 174. Changchun High-Tech Industry Recent Developments
Table 175. Sino Biopharmaceutical Limited Basic Information
Table 176. Sino Biopharmaceutical Limited Biomanufacturing in Pharmaceutical Product Overview
Table 177. Sino Biopharmaceutical Limited Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 178. Sino Biopharmaceutical Limited Business Overview
Table 179. Sino Biopharmaceutical Limited Recent Developments
Table 180. Sobi Basic Information
Table 181. Sobi Biomanufacturing in Pharmaceutical Product Overview
Table 182. Sobi Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 183. Sobi Business Overview
Table 184. Sobi Recent Developments
Table 185. 3SBio Inc. Basic Information
Table 186. 3SBio Inc. Biomanufacturing in Pharmaceutical Product Overview
Table 187. 3SBio Inc. Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 188. 3SBio Inc. Business Overview
Table 189. 3SBio Inc. Recent Developments
Table 190. Beijing Tiantan Biological Basic Information
Table 191. Beijing Tiantan Biological Biomanufacturing in Pharmaceutical Product Overview
Table 192. Beijing Tiantan Biological Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 193. Beijing Tiantan Biological Business Overview
Table 194. Beijing Tiantan Biological Recent Developments
Table 195. Innovent Biologics Basic Information
Table 196. Innovent Biologics Biomanufacturing in Pharmaceutical Product Overview

+357 96 030922
info@marketpublishers.com

Table 197. Innovent Biologics Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 198. Innovent Biologics Business Overview
Table 199. Innovent Biologics Recent Developments
Table 200. Qilu Pharmaceutical Basic Information
Table 201. Qilu Pharmaceutical Biomanufacturing in Pharmaceutical Product Overview
Table 202. Qilu Pharmaceutical Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 203. Qilu Pharmaceutical Business Overview
Table 204. Qilu Pharmaceutical Recent Developments
Table 205. Boehringer Ingelheim Basic Information
Table 206. Boehringer Ingelheim Biomanufacturing in Pharmaceutical Product Overview
Table 207. Boehringer Ingelheim Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 208. Boehringer Ingelheim Business Overview
Table 209. Boehringer Ingelheim Recent Developments
Table 210. BeiGene Basic Information
Table 211. BeiGene Biomanufacturing in Pharmaceutical Product Overview
Table 212. BeiGene Biomanufacturing in Pharmaceutical Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 213. BeiGene Business Overview
Table 214. BeiGene Recent Developments
Table 215. Global Biomanufacturing in Pharmaceutical Sales Forecast by Region (2026-2035) & (K Units)
Table 216. Global Biomanufacturing in Pharmaceutical Market Size Forecast by Region (2026-2035) & (M USD)
Table 217. North America Biomanufacturing in Pharmaceutical Sales Forecast by Country (2026-2035) & (K Units)
Table 218. North America Biomanufacturing in Pharmaceutical Market Size Forecast by Country (2026-2035) & (M USD)
Table 219. Europe Biomanufacturing in Pharmaceutical Sales Forecast by Country (2026-2035) & (K Units)
Table 220. Europe Biomanufacturing in Pharmaceutical Market Size Forecast by Country (2026-2035) & (M USD)
Table 221. Asia Pacific Biomanufacturing in Pharmaceutical Sales Forecast by Region (2026-2035) & (K Units)
Table 222. Asia Pacific Biomanufacturing in Pharmaceutical Market Size Forecast by Region (2026-2035) & (M USD)
Table 223. South America Biomanufacturing in Pharmaceutical Sales Forecast by

+357 96 030922
info@marketpublishers.com

Country (2026-2035) & (K Units)
Table 224. South America Biomanufacturing in Pharmaceutical Market Size Forecast by Country (2026-2035) & (M USD)
Table 225. Middle East and Africa Biomanufacturing in Pharmaceutical Sales Forecast by Country (2026-2035) & (Units)
Table 226. Middle East and Africa Biomanufacturing in Pharmaceutical Market Size Forecast by Country (2026-2035) & (M USD)
Table 227. Global Biomanufacturing in Pharmaceutical Sales Forecast by Type (2026-2035) & (K Units)
Table 228. Global Biomanufacturing in Pharmaceutical Market Size Forecast by Type (2026-2035) & (M USD)
Table 229. Global Biomanufacturing in Pharmaceutical Price Forecast by Type (2026-2035) & (USD/Unit)
Table 230. Global Biomanufacturing in Pharmaceutical Sales (K Units) Forecast by Application (2026-2035)
Table 231. Global Biomanufacturing in Pharmaceutical Market Size Forecast by Application (2026-2035) & (M USD)

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Biomanufacturing in Pharmaceutical
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Biomanufacturing in Pharmaceutical Market Size (M USD), 2025-2035
Figure 5. Global Biomanufacturing in Pharmaceutical Market Size (M USD) (2020-2035)
Figure 6. Global Biomanufacturing in Pharmaceutical Sales (K Units) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Biomanufacturing in Pharmaceutical Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Biomanufacturing in Pharmaceutical Product Life Cycle
Figure 13. Biomanufacturing in Pharmaceutical Sales Share by Manufacturers in 2025
Figure 14. Global Biomanufacturing in Pharmaceutical Revenue Share by Manufacturers in 2025
Figure 15. Biomanufacturing in Pharmaceutical Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Biomanufacturing in Pharmaceutical Average Price (USD/Unit) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Biomanufacturing in Pharmaceutical Revenue in 2025
Figure 18. Industry Chain Map of Biomanufacturing in Pharmaceutical
Figure 19. Global Biomanufacturing in Pharmaceutical Market PEST Analysis
Figure 20. Global Biomanufacturing in Pharmaceutical Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - Imports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Biomanufacturing in Pharmaceutical Market Share by Type
Figure 27. Sales Market Share of Biomanufacturing in Pharmaceutical by Type (2020-2025)
Figure 28. Sales Market Share of Biomanufacturing in Pharmaceutical by Type in 2025
Figure 29. Market Share of Biomanufacturing in Pharmaceutical by Type (2020-2025)

+357 96 030922
info@marketpublishers.com

Figure 30. Market Share of Biomanufacturing in Pharmaceutical by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Biomanufacturing in Pharmaceutical Market Share by Application
Figure 33. Global Biomanufacturing in Pharmaceutical Sales Market Share by Application (2020-2025)
Figure 34. Global Biomanufacturing in Pharmaceutical Sales Market Share by Application in 2025
Figure 35. Global Biomanufacturing in Pharmaceutical Market Share by Application (2020-2025)
Figure 36. Global Biomanufacturing in Pharmaceutical Market Share by Application in 2025
Figure 37. Global Biomanufacturing in Pharmaceutical Sales Growth Rate by Application (2020-2025)
Figure 38. Global Biomanufacturing in Pharmaceutical Sales Market Share by Region (2020-2025)
Figure 39. Global Biomanufacturing in Pharmaceutical Market Size by Region (2020-2025)
Figure 40. North America Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Biomanufacturing in Pharmaceutical Sales Market Share by Country in 2024
Figure 43. North America Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Biomanufacturing in Pharmaceutical Market Size by Country in 2024
Figure 45. U.S. Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Biomanufacturing in Pharmaceutical Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Biomanufacturing in Pharmaceutical Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Biomanufacturing in Pharmaceutical Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Biomanufacturing in Pharmaceutical Market Size (Units) and Growth Rate (2020-2025)

+357 96 030922
info@marketpublishers.com

Figure 51. Europe Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Biomanufacturing in Pharmaceutical Sales Market Share by Country in 2024
Figure 53. Europe Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Biomanufacturing in Pharmaceutical Market Size by Country in 2024
Figure 55. Germany Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Biomanufacturing in Pharmaceutical Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Biomanufacturing in Pharmaceutical Sales Market Share by Region in 2024
Figure 67. Asia Pacific Biomanufacturing in Pharmaceutical Market Size by Region in 2024
Figure 68. China Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)

+357 96 030922
info@marketpublishers.com

Figure 71. Japan Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Biomanufacturing in Pharmaceutical Sales and Growth Rate (K Units)
Figure 79. South America Biomanufacturing in Pharmaceutical Sales Market Share by Country in 2024
Figure 80. South America Biomanufacturing in Pharmaceutical Market Size and Growth Rate (M USD)
Figure 81. South America Biomanufacturing in Pharmaceutical Market Size by Country in 2024
Figure 82. Brazil Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Biomanufacturing in Pharmaceutical Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Biomanufacturing in Pharmaceutical Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Biomanufacturing in Pharmaceutical Market Size and

+357 96 030922
info@marketpublishers.com

Growth Rate (M USD)
Figure 91. Middle East and Africa Biomanufacturing in Pharmaceutical Market Size by Region in 2024
Figure 92. Saudi Arabia Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Biomanufacturing in Pharmaceutical Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Biomanufacturing in Pharmaceutical Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Biomanufacturing in Pharmaceutical Production Market Share by Region (2020-2025)
Figure 103. North America Biomanufacturing in Pharmaceutical Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Biomanufacturing in Pharmaceutical Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Biomanufacturing in Pharmaceutical Production (K Units) Growth Rate (2020-2025)
Figure 106. China Biomanufacturing in Pharmaceutical Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Biomanufacturing in Pharmaceutical Sales Forecast by Volume (2020-2035) & (K Units)
Figure 108. Global Biomanufacturing in Pharmaceutical Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Biomanufacturing in Pharmaceutical Sales Market Share Forecast by Type (2026-2035)

+357 96 030922
info@marketpublishers.com

Figure 110. Global Biomanufacturing in Pharmaceutical Market Share Forecast by Type (2026-2035)
Figure 111. Global Biomanufacturing in Pharmaceutical Sales Forecast by Application (2026-2035)
Figure 112. Global Biomanufacturing in Pharmaceutical Market Share Forecast by Application (2026-2035)

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Biomanufacturing in Pharmaceutical Market Research Report 2026(Status and Outlook)

Product link: https://marketpublishers.com/r/GC58EE4D928CEN.html

Price: US$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GC58EE4D928CEN.html